medroxyprogesterone acetate has been researched along with Age-Related Osteoporosis in 56 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.57) | 18.7374 |
| 1990's | 15 (26.79) | 18.2507 |
| 2000's | 30 (53.57) | 29.6817 |
| 2010's | 9 (16.07) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Green, W | 1 |
| Bahamondes, L; Bahamondes, MV; Dal'Ava, N; Fernandes, A; Modesto, W; Silva dos Santos, P | 1 |
| Canalis, E; Mirza, F | 1 |
| Bahamondes, L; Bahamondes, MV; Modesto, W | 1 |
| Downs, RW; Yazbeck, CF | 1 |
| Emans, SJ; Pitts, SA | 1 |
| de Vernejoul, MC; Sarfati, J | 1 |
| Bérubé, J; Brown, JP; Charbonneau, L; Francoeur, D; Gilbert, A; Gilbert, F; Guilbert, ER; Jacob, R; Kaunitz, AM; Morin, R; Roy, G; Senikas, V; Wagner, MS | 1 |
| Schrager, SB | 1 |
| El-Assal, MA; Farouk, OA; Fathallah, MM; Hussein, M; Mahran, DG; Romih, MS | 1 |
| Britt, RB; Faisel, AJ; Leblanc, AD; Rianon, NJ; Shahidullah, SM | 1 |
| Davidge Pitts, CJ; Kearns, AE | 1 |
| Miller, PD | 1 |
| Heersche, JN; Ishida, Y | 1 |
| Barlow, WE; Ichikawa, LE; LaCroix, AZ; Ott, SM; Scholes, D | 1 |
| Westhoff, C | 1 |
| Hollingworth, BA; Mansour, D; Szarewski, A | 1 |
| Cromer, BA | 1 |
| Cauley, JA; Chen, Z; Cummings, SR; Jackson, RD; LaCroix, AZ; LeBoff, M; Lewis, CE; McGowan, J; Neuner, J; Pettinger, M; Robbins, J; Stefanick, ML; Wactawski-Wende, J; Watts, NB | 1 |
| Aisaka, K | 1 |
| Brodowska, A | 1 |
| Wooltorton, E | 1 |
| Allen, LM; Dizon, CD; Ornstein, MP | 1 |
| Kives, S; Omar, H | 1 |
| Gbolade, BA | 1 |
| Guillebaud, J; Ryan, PJ; Singh, SP | 1 |
| Gold, MA; Hertweck, SP; Lara-Torre, E | 1 |
| Fan, SY; Lo, SS | 1 |
| Bots, ML; Evans, GW; Grobbee, DE; Helmond, FA; McBride, KH; Paskett, ED; Riley, W | 1 |
| Helmond, FA; Landgren, BM; Langer, RD; Rymer, J | 1 |
| El-Mallah, SY; Hassan, M; Mohsen, IA; Seoudi, S; Shaarawy, M | 1 |
| DiVasta, AD; Gordon, CM | 1 |
| Lindsay, R; Pickar, JH; Thorneycroft, IH | 1 |
| Mark, S | 1 |
| Guillebaud, J; Hollingworth, B; Szarewski, A | 1 |
| Newman, MR; Sharma, JB; Smith, RJ | 1 |
| Balasch, J; Castelo-Branco, C; Durán, M; Fortuny, A; Pons, F; Rovira, M; Sierra, J; Vanrell, J; Vives, A | 1 |
| Moghissi, KS | 1 |
| Cundy, T; Reid, IR | 1 |
| McGee, C | 1 |
| Atley, L; Ebeling, PR; Eyre, DR; Lentle, BC; Li, DK; Prior, JC; Vigna, YM; Wark, JD | 1 |
| Isacson, C; New, MI; Newfield, RS; Spitz, IM | 1 |
| Detter, JR; Fowler, SE; Gallagher, JC; Sherman, SS | 1 |
| Cappagli, B; Ciaponi, M; Gambacciani, M; Genazzani, AR | 1 |
| Crisafulli, A; Denuzzo, G; Frisina, N; Gaudio, A; Lasco, A; Meo, A; Morabito, N | 1 |
| Kontula, K | 1 |
| Stone, R | 1 |
| Baylink, DJ; Grecu, EO; Haloran, BP; Simmons, R; Spencer, ME | 1 |
| Cagnacci, A; Felipetto, R; Fioretti, P; Gambacciani, M; Melis, GB; Paoletti, AM; Spinetti, A | 1 |
| Ames, R; Cundy, T; Evans, M; Reid, IR; Roberts, H; Wattie, D | 1 |
| Grecu, EO; Simmons, R; Weinshelbaum, A | 1 |
| Avioli, LV; McCracken, R; McMurtry, C; Pacifici, R; Peck, WA; Rifas, L; Vered, I | 1 |
| Bush, TL; Ernster, VL; Huggins, GR; Hulka, BS; Kelsey, JL; Schottenfeld, D | 1 |
15 review(s) available for medroxyprogesterone acetate and Age-Related Osteoporosis
| Article | Year |
|---|---|
Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.
Topics: Acromegaly; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Autoimmune Diseases; Celiac Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Glucocorticoids; Gonadotropin-Releasing Hormone; Human Growth Hormone; Humans; Hyperparathyroidism, Primary; Hyperthyroidism; Hypogonadism; Inflammatory Bowel Diseases; Medroxyprogesterone Acetate; Multiple Myeloma; Osteoporosis; Thyroxine | 2015 |
Controversies in contraception.
Topics: Adolescent; Contraception; Contraceptive Agents, Female; Female; Humans; Hypertension; Medroxyprogesterone Acetate; Migraine Disorders; Obesity; Osteoporosis; Venous Thromboembolism; Weight Gain | 2008 |
Impact of combined and progestogen-only contraceptives on bone mineral density.
Topics: Bone Density; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Desogestrel; Drug Combinations; Drug Therapy, Combination; Estrogens; Female; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Menarche; Osteoporosis; Progesterone | 2009 |
The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.
Topics: Bone Density; Canada; Contraception; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Osteoporosis; Pregnancy; Pregnancy Rate | 2009 |
DMPA's effect on bone mineral density: A particular concern for adolescents.
Topics: Adolescent; Bone Density; Contraceptive Agents, Female; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Young Adult | 2009 |
Update on medications with adverse skeletal effects.
Topics: Animals; Aromatase Inhibitors; Bone and Bones; Bone Density; Breast Neoplasms; Contraceptive Agents, Female; Diphosphonates; Fractures, Bone; Glucocorticoids; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Osteoporosis; Peroxisome Proliferator-Activated Receptors; Proton Pump Inhibitors; Selective Serotonin Reuptake Inhibitors; Thiazolidinediones | 2011 |
Unrecognized and unappreciated secondary causes of osteoporosis.
Topics: Acidosis, Renal Tubular; Aromatase Inhibitors; Bone and Bones; Contraceptive Agents, Female; Delayed-Action Preparations; Diabetes Complications; Feeding and Eating Disorders; Female; Gastrointestinal Diseases; Humans; Male; Medroxyprogesterone Acetate; Osteoporosis; Proton Pump Inhibitors | 2012 |
Pharmacologic doses of medroxyprogesterone may cause bone loss through glucocorticoid activity: an hypothesis.
Topics: Adolescent; Animals; Bone Density; Female; Glucocorticoids; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Osteoporosis; Postmenopause; Progesterone Congeners; Rats; Receptors, Glucocorticoid | 2002 |
Bone mineral density and DMPA.
Topics: Adult; Body Mass Index; Bone Density; Case-Control Studies; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Prospective Studies; Risk Factors; United States | 2002 |
Bone mineral density in adolescent and young adult women on injectable or oral contraception.
Topics: Adolescent; Adult; Bone Density; Clinical Trials as Topic; Contraceptives, Oral; Contraceptives, Oral, Hormonal; Ethinyl Estradiol; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis | 2003 |
Depo-Provera and bone density.
Topics: Bone Density; Contraceptive Agents, Female; Education, Medical, Continuing; Female; Humans; Injections; Medroxyprogesterone Acetate; Osteoporosis; Risk Factors | 2002 |
Bone loss associated with long-term use of depot medroxyprogesterone acetate.
Topics: Adolescent; Adult; Bone Density; Contraceptive Agents, Female; Contraceptives, Oral, Hormonal; Delayed-Action Preparations; Female; Hong Kong; Humans; Medroxyprogesterone Acetate; Osteoporosis; Practice Guidelines as Topic; Risk Factors; United States; United States Food and Drug Administration | 2005 |
Bone health in adolescents.
Topics: Absorptiometry, Photon; Adolescent; Anorexia Nervosa; Bone and Bones; Bone Density; Contraceptives, Oral; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Ultrasonography | 2006 |
Secondary amenorrhea leading to osteoporosis: incidence and prevention.
Topics: Adolescent; Adult; Algorithms; Amenorrhea; Anorexia Nervosa; Contraceptive Agents, Female; Exercise; Female; Humans; Incidence; Medroxyprogesterone Acetate; Osteoporosis; Patient Education as Topic; Risk Factors | 1997 |
Benefits and risks of menopausal estrogen and/or progestin hormone use.
Topics: Breast Neoplasms; Coronary Disease; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Osteoporosis; Progesterone Congeners; Risk Factors; Uterine Neoplasms | 1988 |
11 trial(s) available for medroxyprogesterone acetate and Age-Related Osteoporosis
| Article | Year |
|---|---|
Exploratory study of the effect of lifestyle counselling on bone mineral density and body composition in users of the contraceptive depot-medroxyprogesterone acetate.
Topics: Adolescent; Adult; Body Composition; Bone Density; Calcium, Dietary; Contraceptive Agents, Female; Counseling; Female; Humans; Life Style; Medroxyprogesterone Acetate; Motor Activity; Osteoporosis; Sunlight; Weight Gain; Young Adult | 2014 |
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial.
Topics: Aged; Bone Density; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Postmenopause; Progesterone Congeners; Proportional Hazards Models; Risk | 2003 |
[Effect of vitamin K2 and estrogen administration on bone formation].
Topics: Amino Acids; Biomarkers; Bone Density; Bone Resorption; Drug Therapy, Combination; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Lumbar Vertebrae; Medroxyprogesterone Acetate; Menopause; Osteocalcin; Osteogenesis; Osteoporosis; Treatment Outcome; Vitamin K 2 | 2004 |
[The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
Topics: Administration, Cutaneous; Adult; Aged; Bone Density; Drug Therapy, Combination; Female; Hormone Replacement Therapy; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Polymorphism, Genetic; Postmenopause; Receptors, Calcitriol; Receptors, Estrogen; Vitamin D | 2003 |
The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study.
Topics: Aged; Atherosclerosis; Double-Blind Method; Estrogen Receptor Modulators; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Osteoporosis; Treatment Outcome; Tunica Intima; Tunica Media | 2006 |
Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study.
Topics: Aged; Biopsy; Contraceptive Agents, Female; Double-Blind Method; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Endometrium; Estrogen Receptor Modulators; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Osteoporosis; Ultrasonography; Uterine Hemorrhage | 2006 |
Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial.
Topics: Adult; Aged; Body Composition; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Women's Health | 2007 |
Add-back therapy in the treatment of endometriosis: the North American experience.
Topics: Administration, Oral; Bone Density; Double-Blind Method; Endometriosis; Estrogen Replacement Therapy; Female; Goserelin; Humans; Medroxyprogesterone Acetate; Osteoporosis; Prospective Studies | 1996 |
Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate.
Topics: Absorptiometry, Photon; Adult; Alkaline Phosphatase; Bone Density; Bone Resorption; Calcium, Dietary; Double-Blind Method; Estrogen Replacement Therapy; Female; Femur; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Ovariectomy; Premenopause; Progesterone Congeners; Thoracic Vertebrae; Weight Gain | 1997 |
Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcifediol; Calcitriol; Calcium; Calcium, Dietary; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Female; Femur; Humans; Hysterectomy; Medroxyprogesterone Acetate; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Placebos; Progesterone Congeners; Spine; Time Factors | 2001 |
Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women.
Topics: Body Weight; Bone Density; Bone Remodeling; Calcium; Dose-Response Relationship, Drug; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Postmenopause | 2001 |
30 other study(ies) available for medroxyprogesterone acetate and Age-Related Osteoporosis
| Article | Year |
|---|---|
The FDA, contraceptive marketing approval and products liability litigation: Depo-Provera and the risk of osteoporosis.
Topics: Advertising; Contraceptive Agents, Female; Drug Approval; Drug Labeling; Female; Humans; Liability, Legal; Medroxyprogesterone Acetate; Osteoporosis; United States; United States Food and Drug Administration | 2013 |
Prevalence of Low Bone Mass and Osteoporosis in Long-Term Users of the Injectable Contraceptive Depot Medroxyprogesterone Acetate.
Topics: Absorptiometry, Photon; Adult; Bone Density; Brazil; Contraceptive Agents, Female; Cross-Sectional Studies; Female; Femur Neck; Humans; Intrauterine Devices, Copper; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Prevalence; Risk Factors; Time Factors | 2015 |
Osteoporosis After Long-Term Depot Medroxyprogesterone: We Need More Data on Fracture Risk.
Topics: Bone Density; Contraceptive Agents, Female; Female; Humans; Intrauterine Devices, Copper; Medroxyprogesterone Acetate; Osteoporosis | 2015 |
ACOG Committee Opinion No. 415: Depot medroxyprogesterone acetate and bone effects.
Topics: Bone Density; Contraceptive Agents, Female; Drug Approval; Female; Fractures, Bone; Humans; Medroxyprogesterone Acetate; Osteoporosis; Time Factors | 2008 |
Bone mineral density in women of a low socioeconomic level using DMPA for contraception in rural Upper Egypt.
Topics: Adult; Bone Density; Bone Diseases, Metabolic; Calcaneus; Contraceptive Agents, Female; Cross-Sectional Studies; Delayed-Action Preparations; Egypt; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Socioeconomic Factors; Time Factors; Ultrasonography; Young Adult | 2010 |
Is poor nutrition masking the effects of depomedroxyprogesterone acetate on bones in adolescent users?
Topics: Absorptiometry, Photon; Adolescent; Body Weight; Bone Density; Confidence Intervals; Contraceptive Agents, Female; Cross-Sectional Studies; Female; Femur Neck; Humans; Logistic Models; Lumbar Vertebrae; Malnutrition; Medroxyprogesterone Acetate; Multivariate Analysis; Nutritional Status; Odds Ratio; Osteoporosis; Risk Factors; Time Factors; Young Adult | 2010 |
Injectable hormone contraception and bone density: results from a prospective study.
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone Density; Cohort Studies; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Injections; Medroxyprogesterone Acetate; Osteoporosis; Prospective Studies | 2002 |
Depo Provera and bone density.
Topics: Contraceptive Agents, Female; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis | 2002 |
Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.
Topics: Adult; Bone Demineralization, Pathologic; Bone Density; Contraceptive Agents, Female; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis | 2005 |
Menstrual and contraceptive issues among young women with developmental delay: a retrospective review of cases at the Hospital for Sick Children, Toronto.
Topics: Adolescent; Child; Contraception; Contraceptive Agents, Female; Developmental Disabilities; Female; Humans; Medroxyprogesterone Acetate; Menstruation; Osteoporosis; Retrospective Studies | 2005 |
Depot medroxyprogesterone acetate (DMPA, Depo-Provera) in adolescents: what is next after the FDA black box warning.
Topics: Adolescent; Bone Density; Contraceptives, Oral, Synthetic; Delayed-Action Preparations; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis | 2005 |
Depot medroxyprogesterone and bone mineral density.
Topics: Absorptiometry, Photon; Adolescent; Adult; Bone Density; Contraceptive Agents, Female; Estradiol; Family Practice; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Prospective Studies; Risk Assessment; Risk Factors | 2002 |
Use of DMPA by adolescents.
Topics: Absorptiometry, Photon; Adolescent; Bone Density; Contraceptive Agents, Female; Dose-Response Relationship, Drug; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Patient Education as Topic | 2005 |
Women's Health Initiative: not over yet. The largest study of women's health has raised at least as many questions as it has answered. Stay tuned.
Topics: Aged; Breast Neoplasms; Calcium, Dietary; Cardiovascular Diseases; Colonic Neoplasms; Diet, Fat-Restricted; Drug Combinations; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Women's Health | 2006 |
Effects of the long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling.
Topics: Adult; Biomarkers; Bone Density; Bone Remodeling; Cohort Studies; Contraceptive Agents, Female; Drug Implants; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Retrospective Studies; Time | 2006 |
Premenopausal bone loss and depot medroxyprogesterone acetate administration.
Topics: Adult; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Premenopause | 1994 |
Depot medroxyprogesterone acetate and osteoporosis. Monitor serum oestradiol concentration in users.
Topics: Bone Density; Estradiol; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis | 1994 |
Depot medroxyprogesterone acetate and osteoporosis. Smoking may explain findings.
Topics: Bone Density; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Smoking | 1994 |
The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation.
Topics: Administration, Cutaneous; Adult; Bone Density; Bone Marrow Transplantation; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Hematologic Neoplasms; Humans; Medroxyprogesterone Acetate; Osteoporosis; Primary Ovarian Insufficiency; Progesterone Congeners; Time Factors | 1996 |
Bone loss and depot medroxyprogesterone.
Topics: Endometriosis; Female; Humans; Medroxyprogesterone Acetate; Osteoporosis; Pelvic Pain | 1997 |
Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia.
Topics: Adolescent; Contraceptives, Oral, Synthetic; Cushing Syndrome; Endometrial Hyperplasia; Female; Glucocorticoids; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Mifepristone; Osteoporosis; Progesterone; Uterus | 2001 |
Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis.
Topics: Adult; beta-Thalassemia; Biomarkers; Bone and Bones; Bone Density; Cross-Sectional Studies; Deferoxamine; Estrogen Replacement Therapy; Female; Femur Neck; Hormone Replacement Therapy; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Iron Chelating Agents; Lumbar Vertebrae; Male; Medroxyprogesterone Acetate; Methyltestosterone; Osteoporosis; Reference Values | 2002 |
Steroid induced osteoporosis.
Topics: Female; Humans; Medroxyprogesterone Acetate; Osteoporosis | 1992 |
Depo-Provera. Controversial contraceptive wins approval from FDA panel.
Topics: Adult; Breast Neoplasms; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Legislation, Drug; Medroxyprogesterone; Medroxyprogesterone Acetate; Osteoporosis; United States; United States Food and Drug Administration; Uterine Neoplasms | 1992 |
Effects of medroxyprogesterone acetate on some parameters of calcium metabolism in patients with glucocorticoid-induced osteoporosis.
Topics: Aged; Alkaline Phosphatase; Calcifediol; Calcitonin; Calcitriol; Calcium; Humans; Insulin-Like Growth Factor I; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Osteoblasts; Osteocalcin; Osteoporosis; Prednisone | 1991 |
Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate.
Topics: Administration, Cutaneous; Administration, Oral; Antineoplastic Agents; Endometrium; Estradiol; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis | 1991 |
Bone density in women receiving depot medroxyprogesterone acetate for contraception.
Topics: Absorptiometry, Photon; Adult; Body Mass Index; Bone Density; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Femur Neck; Humans; Lumbar Vertebrae; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Middle Aged; Osteoporosis; Risk Factors; Smoking; Time Factors | 1991 |
DMPA and bone density.
Topics: Bone Density; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Osteoporosis; Research Design | 1991 |
Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate.
Topics: Aged; Asthma; Bone Density; Humans; Luteinizing Hormone; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis; Prednisone; Testosterone; Time Factors | 1990 |
Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release.
Topics: Adult; Cells, Cultured; Delayed-Action Preparations; Estrogens; Female; Humans; Interleukin-1; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Middle Aged; Monocytes; Osteoporosis; Reference Values; Regression Analysis | 1989 |